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Summary A murine monoclonal antibody PASE/4LJ to prostatic acid phosphatase (PAP) was used to
immunostain a wide variety of sections of benign and malignant tissues (654 blocks). Non-neoplastic adult and
fetal prostatic glands, primary and metastatic prostatic carcinomas, and scattered cells in prostatic and penile
urethra were positive. Rat, dog and rabbit prostates were negative. Nine of 400 tumours of non-prostatic
origin showed some positivity: 6/36 carcinoids, 1/9 islet cell tumours, 1/55 ovarian adenocarcinomas (serous)
and one carcinosarcoma of the lung (epithelial portion). Positive staining was seen in islet cells in 4/5
specimens of normal pancreas, and in 4/9 blocks of normal pancreas surrounding a pancreatic tumour. Loops
of Henle, maculae densae, and distal tubules in 10/10 fetal and 2/9 adult kidneys were also positive, with
proximal tubules and collecting ducts negative. All other 159 blocks of non-neoplastic adult and fetal tissues
were negative. The antibody was also affinity purified from ascitic fluid, and shown not to inhibit the enzyme
activity of prostatic acid phosphatase.
Prostatic carcinoma is the third most common cancer in men,
following lung and skin (OPCS, 1988a), and it is the second
most common cause of male cancer death (OPCS, 1988b).
While localised stage I cancer is usually managed by treat-
ment of the obstructive problems, symptomatic metastatic
disease requires radiotherapy, hormone therapy, and/or
orchidectomy - all with potential morbidity and mortality.
Various problems arise in histopathological diagnosis which
could be elucidated by the use of specific markers for pros-
tatic tissue such as prostatic acid phosphatase (PAP). It may
be difficult to determine whether a metastatic adenocar-
cinoma in a pathological fracture of lymph node is of pros-
tatic origin, or whether an adenocarcinoma in the wall of the
rectum without obvious mucosal involvement is an invading
carcinoma from the prostate, or is of primary rectal origin.
Similarly, deciding whether tumours arising in the region of
the bladder neck are of bladder or prostatic origin may be
difficult histopathologically as well as clinically.
Differentiation of 'atypical' hyperplasia of the prostate from
well differentiated adenocarcinoma would not be expected to
be amenable to this approach.
There are presently two main antigenic markers for pros-
tatic carcinoma, prostate specific antigen (PSA) and prostatic
acid phosphatase (PAP). PSA has been purified (Wang et al.,
1979) and found to be a protein of M, 34 kDa, belonging to
the kallikrein family of serine proteases (Watt et al., 1986). It
can be detected immunocytochemically in normal prostate,
hypertrophic prostates in prostatic carcinoma (Wang et al.,
1979), and also by immunoassay, in the serum of patients
with prostatic carcinoma. Its enzyme activity has not been
demonstrated by histochemical techniques.
PAP (EC 3.1.3.2) is an isoenzyme of acid phosphatase
found in large amounts in the prostate and seminal fluid. The
precise function of PAP is unknown. It has been suggested
that it may act as a hydrolase to split phosphoryl choline in
the semen, and as a transferase (Lunquist, 1946; Mann,
1964). It can be demonstrated by enzyme histochemistry in
frozen sections of tissue (Barka, 1960), but its activity cannot
be retained in paraffin embedded tissue, because it is
inhibited by ethanol (Abul-Fadl & King, 1949). It is also
inhibited by L-tartrate (Abul-Fadl & King, 1949) which has
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led to the development of tartrate labile acid phosphatase
assays. However, this method does not allow specific
identification of PAP since various other tartrate-labile acid
phosphatases have been identified, notably from liver (Saini
& van Etten, 1978), leucocytes (Li et al., 1970; Zwirner et al.,
1986), placenta (Gielselmann et al., 1984), and urine from
pre-pubertal girls (Woljcieszyn et al., 1979).
PAP can be demonstrated immunocytochemically in
routinely fixed surgical material (Burns, 1977; Jobsis et al.,
1978). Polyclonal antibodies may exhibit cross-reactivity with
other tissues, and some rabbit antibodies to PAP have shown
reactivity, by immuno-precipitation, with other tartrate-labile
acid phosphatases (Waheed et al., 1985), some of which are
structurally very similar to PAP. Affinity purification could
remove some cross-reacting antibodies, but not those directed
against epitopes shared with other acid phosphatases.
Monoclonal antibodies (Kohler & Milstein, 1975), have
defined specificity against a single epitope. They can be pro-
duced in large amounts as tissue culture supernatants, which
do not require affinity purification, and with consistent
immunoglobulin reactivity.
The aim of this study was to investigate the possible use
for routine immunohistopathological diagnosis of a mono-
clonal anti-human prostatic acid phosphatase monoclonal
antibody, PASE/4LJ (Haines et al., 1987), by examining its
reactivity towards a wide variety of prostatic and non-
prostatic normal and malignant tissues. We also examined
whether the antibody had any inhibitory effect on PAP
enzyme activity, to determine if it could be of any potential
in an immuno-assisted enzyme assay. The antibody was
initially produced in preference to an anti-PSA antibody, in
order to be able to quantitate and compare immuno-
histochemical staining with acid phosphatase enzyme
histochemistry.
Materials and methods
Prostatic acid phosphatase was purified by ammonium sul-
phate precipitation, concanavalin A chromatography and ion
exchange chromatography, and a monoclonal antibody to
PAP (PASE/4LJ) was produced as previously reported
(Haines et al., 1987). Tissue culture supernatant was used for
immunostaining. Ascitic fluid was produced in the peritoneal
cavity of pristane primed Swiss A2G mice by intraperitoneal
injection of 5 x 107 hybridoma cells. Fluid was removed after
10-14 days, centrifuged and stored at - 20°C.
Purified PAP (5.6 mg) was coupled to 5 ml Affi-gel 15
according to the method recommended in the manufacturer's
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Affinity purified antibody was produced from ascites by
applying ascitic fluid diluted 1:1 in PBS to a column of
PAP-coupled Affi-gel 15. The column was washed with PBS,
and specific antibody eluted with 3 M guanidine hydro-
chloride. Pooled fractions were dialysed against PBS, and
then distilled water, and lyophilised.
Preparation ofnegative control antibody
An absorbed control supernatant was prepared by incubating
1 ml of PASE/4LJ supernatant with I ml of PAP-coupled
Affi-gel 15 agarose beads. The supernatant was separated
from the beads by centrifugation and then used at the same
dilution as the positive antibody. As a control for non-
specific binding to Affi-gel 15, PASE/4LJ supernatant was
similarly incubated with Affi-gel 15 coupled to ovalbumin
and also to Affi-gel 15 blocked only with ethanolamine-HC1.
Test ofinhibition ofPAP by monoclonal antibody
Doubling dilutions in 1% ovalbumin in PBS from
0.85mgml1' to 1.6ligml-' of affinity purified PASE/4LJ,
mouse IgG (Sigma Chemical Co. Ltd, Dorset), and an
irrelevant mouse monoclonal antibody to human chorionic
gonadotropin (beta-HCG; Unipath, Herts.) were each
incubated in 96-well microtitre plates with 1 tg ml-' of
purified PAP (total volume 150tl) for 2 h at room
temperature. Acid phosphatase activity was assayed by a
standard method (van Etten & Saini, 1977), except that the
assay was carried out in microtitre plates and only 20.d of
sample was used, volumes of other reagents being reduced
accordingly. Absorbence at 410 nm was measured using a
plate reader (Dynatech Laboratories Ltd, Sussex).
Tissues
Routinely processed formalin-fixed paraffin-embedded blocks
were selected from both male and female patients. These
consisted of 32 primary tumours of the prostate, 11 meta-
static prostate carcinomas, 12 hyperplastic prostates, 402
benign and malignant tumours of other organs, and 191
blocks of non-neoplastic non-prostatic tissues. In addition,
eight animal prostates (from dog, rabbit and rat) were
selected.
Cryostat sections of non-neoplastic prostatic chippings
were prepared, and chippings from another patient were fixed
in unbuffered formalin, phosphate buffered formalin, formal
acetic acid, Bouin's, formal sublimate or methacarn, and
processed to paraffin wax. Other chippings were fixed in
unbuffered formalin and treated with either of two
decalcification protocols; 33% (v/v) formic acid in 12.5%
(w/v) citric acid for 2 days, or 12.5% (w/v) EDTA for 2 days
and then wax embedded.
Immunocytochemistry
Sections of 4 pm were immunostained using an indirect
immunoperoxidase technique (Heyderman et al., 1986), with
tissue culture supernatant diluted 1:10 in PBS-OA, and a
sheep anti-mouse horseradish peroxidase conjugate (Amer-
sham International plc, Bucks.) diluted 1:40 in PBS-OA. A
positive control slide of hyperplastic prostate was included
with each group of sections stained. The presence of normal
tissue adjacent to tumour was noted and included with the
normal tissue results.
Fetal and adult normal kidneys were also stained by the
streptavidin-biotin ABC method, using PASE/4LJ diluted
1:100 in PBS-OA, and biotinylated horseradish peroxidase
and streptavidin (Hsu et al., 1981) (Dako Ltd, Bucks.). This
dilution of antibody was found to produce strong positive
staining in the control slide of prostate. Staining of the
kidneys was then repeated at a dilution of 1:10.
Sequential sections of each positive block were restained
with PASE/4LJ, and with the negative absorbed control
reagent. A control block of hyperplastic prostate was also
stained with the PASE antibody incubated either with Affi-
Gel 15 coupled to mouse immunoglobulin, or to ovalbumin.
A Perls stain (Stevens, 1982) was carried out to confirm
the presence of iron on the sections in which a greenish
brown pigment was present. Sections containing an
unidentified brownish pigment in negative controls, inter-
preted as probably being lipofuscin, were stained by the
Schmorl method (Stevens, 1982).
The antibody was also used for 6 months in the routine
immunocytochemistry laboratory in parallel with an affinity
purified rabbit polyclonal antibody to PAP (Heyderman et
al., 1984). The same indirect technique was used.
Results
Inhibition ofPAP
PASE/4LJ had no effect on the enzyme activity of PAP;
neither did mouse IgG or the irrelevant monoclonal antibody
to beta-HCG at up to 800-fold molar excess of immuno-
globulin over PAP.
Tissue staining
A total of 658 blocks of tissues were stained with the mono-
clonal antibody, PASE/4LJ (see Tables I, II and III). All 12
benign, 32 malignant, 11 metastatic and two fetal prostates
were positive (Figures 1, 2 and 3). There were always some
negative areas of epithelium, and the intensity of staining
varied, generally being weaker in carcinomas than in hyper-
plastic prostates. Staining was seen in scattered cells within
the urothelium of adult, Letal prostatic and penile urethra
(5/6) (Figure 4). There was a variable degree of staining of
prostatic fibromuscular stroma, though smooth muscle
elsewhere was negative.
Nine of 402 non-prostatic neoplasms were positive. The
staining in these tissues varied in intensity, but in none was it
as strong as in prostatic epithelium. Six of 36 carcinoids, 1/55
ovarian adenocarcinomas (a serous adenocarcinoma), 1/1
carcinosarcoma of the lung (adenocarcinomatous foci) and
1/9 islet cell tumours were positive. There was staining of
islet cells in 4/5 blocks of normal pancreas (Figure 6) and in
4/9 blocks of non-neoplastic pancreas surrounding tumour.
In addition, the loops of Henle, maculae densae and distal
tubules in 10/10 fetal kidneys (Figure 5) and 2/9 adult
kidneys were positive, while proximal tubules and collecting
ducts were negative. Three of 10 fetal kidneys and 1/2
positive adult kidneys were from females. Staining of fetal
kidney was stronger than that in adult kidney.
The fetal and adult kidneys and positive hyperplastic con-
trol section were also positive when the ABC method was
used with the antibody diluted 1:100. No additional adult
kidneys were positive even when the primary antibody was
used at a dilution of 1:10, i.e. at 10 times the concentration
required for strong staining of the control hyperplastic pros-
tate.
Table I Tissues positively stained with monoclonal antibody to
prostatic phosphatase PASE/4LJ
All normal and hyperplastic prostatectomy specimens (12) plus non-
neoplastic prostatic glands included in bladder biopsies, all primary
adenocarcinomas of the prostate (32), scattered cells in prostatic,
bulbar and penile urethra (5/6), prostatic carcinoma invading
rectum (1), prostatic metastase to lymph nodes (5) and bone (5).
1/55 ovarian carcinomas (1/29 serous, 0/5 mucinous, 0/6 clear cell, 0/9
endometrioid, 0/6 poorly differentiated).
6/36 carcinoids (1/2 colorectal, 1/7 appendix, 4/12 small bowel, 0/3
stomach, 0/11 lung, 0/1 testis).
1/9 pancreatic islet cell tumours (an islet cell carcinoma).
Pancreatic islets - cells stained in some islets (4/5 blocks of normal
pancreas, 4/9 blocks ofuninvolved pancreassurroundingpancreatic
tumour).
Kidney - staining ofloops ofHenle, maculae densae, and distal tubules
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Table II Tumours negative for PAP (total 393/402)
Urinary tract (20) - transitional cell carcinoma of the bladder (12),
adenocarcinoma ofthebladder(2), transitional cellcarcinomaofthe
ureter (1), transitional cell carcinoma oftheprostate (1), hyperneph-
roma (5), nephroblastoma (1).
Genital tract (78) - testicular teratoma (4), testicular teratoma plus
seminoma (1), seminoma (3), testicular yolk sac tumour (1),
carcinoma of the cervix (5), endometrial adenocarcimona (4),
ovarian choriocarcinoma (1), dysgerminoma (1), ovarian yolk sac
tumour (2), fibroids (2), ovarian adenocarcinomas: serous (28
negative, I positive), mucinous (5), clear cell (6), endometroioid (9),
poorly differentiated (6).
Endocrine organs (62) - adrenal carcinoma (5), adrenal cortical
adenoma (7), phaeochromocytoma (6), islet cell adenoma (3), islet
cell carcinoma (5 negative, 1 positive), pituitary adenoma (4),
thyroid adenoma (1), parathyroid adenoma (6), carcinomas ofthe
thyroid: anaplastic (5), follicular (7), papillary (8), medullary (5).
Carcinoids (30) - appendix (6 negative, 1 positive), colorectal (1
negative, I positive), ileum (8 negative, 4 positive), lung (I1),
stomach (3), testis (1).
Bone, muscle and soft tissue (38) - chondrosarcoma (4), chordoma (2),
exostosis and osteoid osteoma (3), non-ossifying fibroma (4),
osteoclastoma (6), osteosarcoma (2), dermatofibrosarcoma pro-
truberans (1), epitheloid sarcoma (92), liposarcoma (4), malignant
fibrous histiocytoma (3), malignant nerve sheath tumour (2),
rhabdomyosarcoma (3), synovial sarcoma (2).
Breast (32) - fibroadenoma (5), ductal carcinoma (10 female and 2
male), lobular (9), medullary (2), cystosarcoma phylloides (4).
Gastrointestinal tract (44) - colorectal carcinoma (12), gastric car-
cinoma (7), pancreatic adenocarcinoma (8), hepatocellular car-
cinoma (3), hepatoblastoma (2), salivary gland tumours: adenocar-
cinoma (3), adenocystic carcinoma (4), mucoepidermoid carcinoma
(2), acinic cell tumour (2), pleomorphic adenoma (1).
Respiratory system (36) - lung adenocarcinoma (17), lung squamous
carcinoma (2), lung large cell anaplastic carcinoma (4), lung oat cell
carcinoma (2), bronchio-alveolar carcinoma (1), mesothelioma (10).
Lympho-proliferative system (17) - lymphoma non-Hodgkin's (8),
Hodgkin's (5), chloroma (2), thymoma (2).
Skin(17) - basalcellcarcinoma (3),squamouscarcinoma(3),sebaceous
carcinoma (3), malignant eccrine poroma (3), Merkel cell tumour
(2), secondary melanoma in nodes (2).
Nervous system (18) - astrocytoma (6), medulloblastoma (3), epen-
dymona (2), choroid plexus tumour (1), craniopharyngioma (1),
meningioma (5).
Table III Normal and non-neoplastic tissues negative for prostatic
acid phosphatase
Adult tissues
Either part of a larger resection specimen for a non-malignant
condition, from uninvolved tissue surrounding tumour, or from
autopsy material.
Genitourinary system - kidney, ureter, bladder, ovary, testis, endomet-
rium (proliferative, secretory, 'pill' type, atrophic), myometrium,
breast (normal, lactating, fibrocystic disease, gynaecomastia).
Lympho-proliferative system - tonsil, thymus, lymph nodes, spleen,
bone marrow.
Musculoskeletal and nervous system - striated and smooth muscle,
bone, cartilage.
Cardiovascular and respiratory system - veins, arteries, cardiac muscle,
lung parenchyma, bronchus, pleura.
Endocrine and glandular tissue - pituitary, thyroid, adrenal,
parathyroid, salivary glands.
Gastrointestinal tract - oesophagus, stomach, small and large bowel
including rectum.
Nervous system - cerebrum, cerebellum, spinal cord, eye.
Fetal tissues
Lung, liver, spleen, ovary, testis, adrenal, bladder, heart, gallbladder,
pancreas, thymus, thyroid, brain, first, second and third trimester
placenta, umbilical cord.
Animal tissues
Prostates from dog, rabbit and rat.
Staining of all of the previously positive sections was
repeated and in parallel with the control absorbed antibody
absorbed with PAP coupled Affi-gel 15. All remained positive
with PASE/4LJ, and were negative with the control antibody,
although there was iron pigment in some sections and
unidentified pigment, probably lipofuscin, in others, present
in both test and control sections. Incubation of the mono-
clonal antibody with Affi-gel 15, either coupled to ovalbumin
or with the active sites blocked with ethanolamine, did not
reduce the intensity of staining of the positive control
hyperplastic prostate, confirming the specificity of the
absorption procedure.
Staining was observed in keratinised cells in skin sections.
This staining was not present when the absorbed control
antibody was used. However, it was not regarded as specific
since it has been seen when other monoclonal antibodies such
as anti-CEA were used (Haines et al., unpublished data).
This may represent either non-specific binding of mouse Ig,
or binding of IgG to Fc receptors still present in fixed tissues
(Garvin et al., 1974).
Hyperplastic prostatic chippings, frozen and unfixed, fixed
in each of the seven different fixatives, or treated with either
of the two decalcification protocols, stained positively, as did
bone trephines from deposits of metastatic prostatic tumour
decalcified in EDTA or in formic/citric acid. The antibody
did not stain any of the eight animal prostates (four dog,
three rat, one rabbit); neither did it stain sections of one of
the canine prostates fixed in each of seven fixatives.
Unidentified pigment was seen in some endocrine cells,
particularly the parathyroids, and in one islet cell tumour,
and it was present in both the test and the negative control
slides. It stained positively with a Schmorl stain, and was
interpreted as possibly lipofuscin, but not identified further.
Perls stains confirmed the presence of haemosiderin in areas
considered to contain iron in immunostained preparations.
PASE/4LJ produced comparable staining to the rabbit
anti-PAP antibody in all the tissues tested for PAP in the
routine immunocytochemistry laboratory.
Discussion
This report describes a murine monoclonal antibody to pro-
static acid phosphatase, PASE/4LJ, which can be used to
immunostain frozen sections, paraffin-embedded tissue fixed
in a variety of fixatives, and decalcified blocks. All of the
primary and metastatic prostatic carcinomas were positive,
and gastrointestinal and transitional cell carcinomas were
negative, indicating that the absence of PAP would make the
diagnosis of a prostatic primary or secondary most unlikely.
However, positivity was seen in some non-prostatic malig-
nant and normal tissues.
The presence of PAP positive cells in the penile and pros-
tatic urethra would explain the occurrence of 'ectopic' pros-
tatic tissue in these sites. Haematuria and dysuria have been
associated with their presence (Heyderman et al., 1987).
The antibody shares the previously described recognition
of an epitope(s) in some carcinoids of the gastrointestinal
tract (Sobin et al., 1986), pancreatic islet cells, and islet cell
tumours (Choe et al., 1978; Jobsis et al., 1981; Yam et al.,
1981; Cohen et al., 1983). The proportion of gastrointestinal
carcinoids positive for PAP appears to be maximal distally
(Sobin et al., 1986), and the positivity of rectal carcinoids
may be a problem if the antibody is to be used for the
differential diagnosis of tumours involving the wall of the
rectum with no apparent mucosal origin. Positive staining for
both prostatic acid phosphatase and prostate specific antigen
have been reported in 'carcinoid-like' tumours of the prostate
which are argyrophilic, but lack other markers of neuren-
docrine differentiation (Ansari et al., 1981; Almagro et al.,
1986). Dispute as to whether or not these should be con-
sidered 'true' carcinoids remains.
Staining was seen in the loops of Henle, maculae densae
and distal tubules of all 10 fetal kidneys and in 2/9 adult
kidneys. The staining could not be detected in the seven
negative adult normal kidneys even when the ABC method
was used at a 10 times higher concentration of PASE/4LJ
normally used for this method. The staining was not sex-
specific, since 3/10 fetal kidneys and 1/2 positive adult
kidneys were from females. The antibody was therefore
unlikely to be demonstrating material derived from the pros-
tate, and absorbed by the renal tubules. It may represent
recognition of a renal acid phosphatase or an epitope on an890 A.M.R. HAINES et al.
Figure 1 Specimen of benign prostatic hypertrophy showing Figure 2 Residual benign prostatic glands encircled by well
good discrimination of staining between epithelial cells and differentiated prostatic adenocarcinoma. In this field there is pat-
stroma. In some specimens, staining of prostatic fibromuscular chy staining of non-neoplastic epithelium, with more uniform
stroma was more marked. x 45. staining of the tumour. In most other specimens, benign glands
were more intensely stained than tumour. x 45.
Figure 3 Decalcified bone trephine through deposit of osteos-
clerotic metastatic prostatic carcinoma. The tumour is positive;
asteoblasts rimming the bone trabeculae are negative. x 75.
Figure 5 Fetal kidney (female) with glomeruli negative, and
loops of Henle positive. x 75.
Figure 4 Penile urethra showing focal differentiation of epi-
thelium into prostatic acid phosphatase secreting cells. There is
surrounding fibrosis in this specimen with some distortion of the
lumen. x 45.
Figure 6 Section of normal pancreas showing staining of some
cells in all of the islets. x 75.IMMUNOCYTOCHEMISTRY FOR PAP WITH PASE/4LJ ANTIBODY 891
unrelated molecule. Since both intensity and occurrence of
staining were less in adult than fetal kidneys, the epitope
could be related to differentiation. A study of fetal kidneys at
various gestation ages would be required to investigate this
further.
Staining of some renal tubules has also been reported with
monoclonal antibodies raised against antigens other than
PAP or PSA (Frankel et al., 1982a), as well as with some
monoclonal anti-PSA antibodies (Frankel et al., 1982b), and
polyclonal PAP antisera (Yam et al., 1981). Frankel et al.
explained staining of the kidney as being due to non-
idiotypic binding of the mouse immunoglobulin to a recep-
tor(s) on tubule epithelium. However, staining of similar
tissues with an anti-EMA monoclonal antibody (Heyderman
et al., 1985) showed a different pattern of distribution, with
distal and collecting tubules positive (Cordell et al., 1985).
Localisation in specific areas of the renal tubules may be of
diagnostic use for differentiating between the various regions
of the nephron in damaged kidneys, when the distal tubules
may be difficult to distinguish from the vasa recta.
One ovarian adenocarcinoma and one pulmonary carcino-
sarcoma were positive, but positivity in an ovarian carcinoma
is not likely to give rise to diagnostic problems. Although 26
epithelial lung tumours were negative, the carcinosarcoma
showed weak positivity in the adenocarcinomatous portion.
It would be most unusual for a prostatic carcinoma to
present initially with a lung deposit and no evidence of a
prostatic primary, but the antibody might be of limited value
in the differential diagnosis of primary adenocarcinoma of
the lung from a prostatic metastasis. However, staining in
these two tumours was extremely weak, unlike that seen in
tissues of prostatic origin (Figures 1-3).
The colorectal, transitional cell carcinomas and bladder
adenocarcinomas were all negative with PASE/4LJ mono-
clonal antibody, indicating its value in the differential
diagnosis of tumours arising in rectum, prostate and bladder.
In general, transitional carcinomas of the bladder may be
identified by their characteristics morphology, but glandular
metaplasia and/or diathermy artefact may make the diag-
nosis difficult, especially around the bladder neck.
The antibody did not stain canine prostates, although
staining of canine prostates with anti-human PAP antibodies
has been reported (McEntee et al., 1987), nor did it stain
those of rat or rabbit. However, the number studied was
small and a much larger study might well reveal activity in
some instances.
Staining of a variety of other tissues has been noted in
previous reports using polyclonal antisera to PAP. With the
PASE/4LJ monoclonal antibody no staining was seen in
granulocytes (Yam et al., 1981), osteoclasts (Jobsis et al.,
1981), parietal cells of the stomach, liver cells, renal cell or
breast carcinomas (Li et al., 1980; Yam et al., 1981).
Antisera to prostate specific antigen may be superior for
monitoring of disease progression by serum RIA (Stamey et
al., 1987). In some reports more prostatic tumours appear to
stain positively for PAP than for PSA (Vernon & Williams,
1983; Keillor & Aterman, 1987), while in others more were
positive for PSA (Allhoff et al., 1983; Shah et al., 1985).
These different results may well reflect differences in the
antibodies used for immunostaining.
PASE/4LJ does not inhibit the enzyme activity of PAP and
is therefore unlikely to bind to the active site. This indicates
that the antibody could be of potential use in an immuno-
assisted enzyme assay for PAP in serum.
In conclusion, the antibody has proved a useful addition to
our diagnostic histopathology armamentarium, being used
successfully in this department for the differential diagnosis
of primary prostatic, bladder and rectal carcinomas, and for
the investigation of metastatic deposits of tumours of un-
known origin.
This study would not have been possible without the support and
encouragement of Sir Denis Hamilton and Dr David Collins. We
should like to thank our colleagues for providing blocks or sections
of tissues difficult for us to obtain, and the technical staff of the
Department of Histopathology for cutting many of the sections
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